{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:39:25Z","timestamp":1761183565728,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016291","name":"National Astronomical Research Institute of Thailand","doi-asserted-by":"publisher","award":["NRCT5-RSA63004-13"],"award-info":[{"award-number":["NRCT5-RSA63004-13"]}],"id":[{"id":"10.13039\/100016291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.dmpk.2022.100478","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T12:34:15Z","timestamp":1666182855000},"page":"100478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-9599","authenticated-orcid":false,"given":"Piyawat","family":"Chaivichacharn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9611","authenticated-orcid":false,"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivaporn","family":"Gatechompol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasiwimol","family":"Ubolyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baralee","family":"Punyawudho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2022.100478_bib1","series-title":"Thailand National Guidelines on HIV\/AIDS Diagnosis, treatment and Prevention 2020","first-page":"1","author":"Ruxrungtham","year":"2020"},{"issue":"9","key":"10.1016\/j.dmpk.2022.100478_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/00002030-200406180-00009","article-title":"Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir\/ritonavir (KALEPHAR study)","volume":"18","author":"Breilh","year":"2004","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100478_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/AAC.47.1.350-359.2003","article-title":"Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients","volume":"47","author":"Hsu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.dmpk.2022.100478_bib4","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/AAC.46.9.2926-2932.2002","article-title":"Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients","volume":"46","author":"Masquelier","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/088922204322996509","article-title":"Prediction of virological response to lopinavir\/ritonavir using the genotypic inhibitory quotient","volume":"20","author":"Gonzalez de Requena","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00126334-200308150-00007","article-title":"Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir\/ritonavir-containing regimens","volume":"33","author":"Gutierrez","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.dmpk.2022.100478_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/108729103322395465","article-title":"Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir\/ritonavir","volume":"17","author":"Gonzalez de Requena","year":"2003","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100478_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/135965350400900105","article-title":"Changes in body fat composition after 1 year of salvage therapy with lopinavir\/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations","volume":"9","author":"Gutierrez","year":"2004","journal-title":"Antivir Ther"},{"issue":"11","key":"10.1016\/j.dmpk.2022.100478_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"year":"2015","key":"10.1016\/j.dmpk.2022.100478_bib10"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.ftd.0000245681.12092.d6","article-title":"A\u00a0retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults","volume":"28","author":"van der Leur","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/AAC.47.3.986-990.2003","article-title":"High variability of plasma drug concentrations in dual protease inhibitor regimens","volume":"47","author":"Guiard-Schmid","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dki209","article-title":"Safety and antiviral activity of lopinavir\/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection","volume":"56","author":"Kaplan","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"26","key":"10.1016\/j.dmpk.2022.100478_bib14","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3851\/IMP3101","article-title":"Hyperlipidaemia in HIV-infected patients on lopinavir\/ritonavir monotherapy in resource-limited settings","volume":"22","author":"Matoga","year":"2017","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3851\/IMP1414","article-title":"A\u00a0population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients","volume":"14","author":"Bouillon-Pichault","year":"2009","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FTD.0b013e31822d578b","article-title":"Population pharmacokinetics of lopinavir\/ritonavir (Kaletra) in HIV-infected patients","volume":"33","author":"Lopez Aspiroz","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2125.2004.02241.x","article-title":"Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients","volume":"59","author":"Kappelhoff","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100478_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2125.2005.02455.x","article-title":"Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients","volume":"60","author":"Crommentuyn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2022.100478_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200847100-00005","article-title":"Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults","volume":"47","author":"Molto","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100478_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FPC.0b013e328336eee4","article-title":"ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir","volume":"20","author":"Lubomirov","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/pme.14.58","article-title":"Population pharmacokinetic\/pharmacogenetic model of lopinavir\/ritonavir in HIV-infected patients","volume":"11","author":"Lopez Aspiroz","year":"2014","journal-title":"Per Med"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100478_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bcpt.13154","article-title":"Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV","volume":"124","author":"Niu","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.clinthera.2020.04.013","article-title":"Dosage optimization of efavirenz based on a population pharmacokinetic-pharmacogenetic model of HIV-infected patients in Thailand","volume":"42","author":"Chaivichacharn","year":"2020","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100478_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2008.244","article-title":"A\u00a0low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults","volume":"85","author":"Avihingsanon","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100478_bib26","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/S2352-3018(16)30010-8","article-title":"Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial","volume":"3","author":"Bunupuradah","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/QAI.0b013e31817cfdc9","article-title":"Low-dose, once-daily atazanavir\/ritonavir (200\/100): an effective treatment for HIV-infected patients in Thailand","volume":"49","author":"Chetchotisakd","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijantimicag.2016.11.019","article-title":"Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients","volume":"49","author":"Punyawudho","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/jac\/dkn050","article-title":"Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults","volume":"61","author":"van der Lugt","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100478_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAI.0b013e31823ba736","article-title":"Neither branded nor generic lopinavir\/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200\/50 mg twice daily","volume":"59","author":"Ramautarsing","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkq468","article-title":"Pharmacokinetics of plasma lopinavir\/ritonavir following the administration of 400\/100 mg, 200\/150 mg and 200\/50 mg twice daily in HIV-negative volunteers","volume":"66","author":"Jackson","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2011.04154.x","article-title":"Model-based approach to dose optimization of lopinavir\/ritonavir when co-administered with rifampicin","volume":"73","author":"Zhang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.dmpk.2022.100478_bib33","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e328356480d","article-title":"Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients","volume":"26","author":"Praditpornsilpa","year":"2012","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"Bergstrand","year":"2009","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100478_bib36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100478_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-016-9496-7","article-title":"dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap","volume":"43","author":"Dosne","year":"2016","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100478_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100478_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3851\/IMP2324","article-title":"Pharmacokinetics and 48-week safety and efficacy of generic lopinavir\/ritonavir in Thai HIV-infected patients","volume":"18","author":"Ramautarsing","year":"2013","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100478_bib41","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200101050-00002","article-title":"ABT-378\/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results","volume":"15","author":"Murphy","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100478_bib42","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.00887-10","article-title":"Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies","volume":"55","author":"Dickinson","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100478_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40262-013-0122-1","article-title":"Integrated population pharmacokinetic\/viral dynamic modelling of lopinavir\/ritonavir in HIV-1 treatment-naive patients","volume":"53","author":"Wang","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2022.100478_bib45","unstructured":"Center for Disease Control and Prevention (CDC). Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from: https:\/\/www.cdc.gov\/tb\/publications\/guidelines\/tb_hiv_drugs\/pdf\/tbhiv.pdf."},{"issue":"8","key":"10.1016\/j.dmpk.2022.100478_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"Aids"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.dmpk.2022.100478_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100478_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","article-title":"The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes","volume":"199","author":"Parkinson","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-018-2450-4","article-title":"Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries","volume":"74","author":"van Dyk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3851\/IMP2741","article-title":"Population pharmacokinetics of nevirapine in Thai HIV-infected patients","volume":"19","author":"Wattanakul","year":"2014","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100478_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing Protocols to study Intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and De-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J"},{"issue":"17","key":"10.1016\/j.dmpk.2022.100478_bib53","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1097\/QAD.0b013e328332c3a5","article-title":"How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials","volume":"23","author":"Hill","year":"2009","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100478_bib54","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.01598-10","article-title":"Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets","volume":"55","author":"Decloedt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"10.1016\/j.dmpk.2022.100478_bib55","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00002030-200210180-00015","article-title":"Clinical use of lopinavir\/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics","volume":"16","author":"Boffito","year":"2002","journal-title":"Aids"},{"issue":"12","key":"10.1016\/j.dmpk.2022.100478_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17512433.2016.1235972","article-title":"Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients","volume":"9","author":"Punyawudho","year":"2016","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:56:55Z","timestamp":1761163015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436722000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":56,"alternative-id":["S1347436722000350"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100478","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100478"}}